ID: ALA1081558

Max Phase: Preclinical

Molecular Formula: C22H22N4O4

Molecular Weight: 406.44

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(/C=N/CCNC2=N/C(=C\c3ccc4c(c3)OCO4)C(=O)N2C)cc1

Standard InChI:  InChI=1S/C22H22N4O4/c1-26-21(27)18(11-16-5-8-19-20(12-16)30-14-29-19)25-22(26)24-10-9-23-13-15-3-6-17(28-2)7-4-15/h3-8,11-13H,9-10,14H2,1-2H3,(H,24,25)/b18-11-,23-13+

Standard InChI Key:  HYZCCPWOMHLGOG-WJBQSONESA-N

Associated Targets(Human)

Casein kinase I isoform alpha/subunit beta 18 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cyclin-dependent kinase 5/CDK5 activator 1 3697 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glycogen synthase kinase-3 736 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 406.44Molecular Weight (Monoisotopic): 406.1641AlogP: 2.30#Rotatable Bonds: 6
Polar Surface Area: 84.75Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.41CX LogP: 2.46CX LogD: 2.42
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.45Np Likeness Score: -0.53

References

1. Debdab M, Renault S, Lozach O, Meijer L, Paquin L, Carreaux F, Bazureau JP..  (2010)  Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors.,  45  (2): [PMID:19879673] [10.1016/j.ejmech.2009.10.009]

Source